Dyslipidemia, a modifiable risk factor for atherosclerotic cardiovascular disease, can be effectively addressed through lifestyle modifications and/or lipid-lowering therapies. However, the clinical use of statins may pose challenges for some patients due to potential side effects such as statin-associated muscle symptoms. Consequently, there is a growing interest in integrative cardiology and the use of nutraceuticals as an alternative or complementary approach to managing dyslipidemia. This interest is driven by patients seeking a more natural approach to their condition. In this context, nutraceuticals have garnered attention as potential agents for dyslipidemia management, both in patients with and without established atherosclerotic cardiovascular disease. To shed light on this area, we present an updated review of the evidence surrounding various new and emerging nutraceuticals. We delve into their mechanism of action, lipid-lowering effects, and potential side effects. Some of these nutraceuticals include red yeast rice, bergamot, and others.